The assignment of a unique, permanent J-code by the U.S. Centers for Medicare and Medicaid Services is a critical regulatory milestone for Glaukos' iDose TR. It simplifies the reimbursement process for healthcare providers, potentially leading to increased adoption and sales. This development is directly relevant to Glaukos and is likely to have a positive impact on its stock price in the short term due to the enhanced marketability and potential for increased revenue.